MiraLAX Disease Interactions
There are 3 disease interactions with MiraLAX (polyethylene glycol 3350).
Laxatives (applies to MiraLAX) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
References
- (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- (2001) "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc
- (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
- (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
Laxatives (applies to MiraLAX) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
References
- (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- (2001) "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet
- (2001) "Product Information. Citrucel (methylcellulose)." SmithKline Beecham
- (2001) "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc
- (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
- (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
PEG solutions (applies to MiraLAX) GI obstruction/perforation
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Perforation, Ulcerative Colitis
The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.
References
- Raymond PL (1991) "Mallory-Weiss tear associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc, 37, p. 410-1
- McBride MA, Vanagunas A (1993) "Esophageal perforation associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc, 39, p. 856-7
- "Product Information. Golytely (polyethylene glycol 3350 with electrolytes)." Braintree
- (2016) "Product Information. GlycoLax (polyethylene glycol 3350)." DispenseXpress Inc
MiraLAX drug interactions
There are 219 drug interactions with MiraLAX (polyethylene glycol 3350).
More about MiraLAX (polyethylene glycol 3350)
- MiraLAX consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (259)
- Side effects
- Dosage information
- During pregnancy
- Support group
- Drug class: laxatives
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.